DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
about
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesPharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsUnderstanding and overcoming metformin gastrointestinal intolerance.The effects of glucose-lowering therapies on diabetic kidney diseaseUse of metformin and vildagliptin for treatment of type 2 diabetes in the elderlyBenefits of healthy adipose tissue in the treatment of diabetes.Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients.Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study.Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian SubjectsCombination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study.Efficacy of initial Basal-supported oral therapy with sitagliptin in untreated type 2 diabetes.The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsPharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.Glucagon-like peptide-1 and its cardiovascular effects.Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.Cardiovascular effects of gliptins.Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Efficacy and safety of Jentadueto® (linagliptin plus metformin).The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.Linagliptin: from bench to bedside.Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.DPP-4 inhibitors: pharmacological differences and their clinical implications.Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.The power of two: an update on fixed-dose combinations for type 2 diabetes.Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.
P2860
Q24628948-FD94CEA2-387F-4FBD-AD5A-0B69D710DF75Q26749524-A0070C73-9AE9-43B2-8A76-05757F3E92EDQ30240030-FEFC74EF-7544-477B-AEB8-3A5457997AA6Q33583220-721BFDD8-190D-45F7-B643-6D4E305096D8Q33800171-0BE34D7F-EF8C-4922-934B-4A08BB5F6DDBQ34023537-BB3EA93A-D90D-4697-9E6E-F1377A60CD49Q35126858-60407C5A-B87B-499D-90CC-D1095DC95027Q35772558-6E375B72-DD06-490E-88F2-1D8401245EF4Q36170755-854A13FF-1877-4ECF-BFFE-C7C6ABACE70CQ36303346-D920B809-0D29-489C-9FA1-F60C70DD687AQ36989711-45420E6B-7389-41BA-A580-5333EB948885Q37142980-515D56F6-F99B-4C2D-94AA-268DEBCF7C15Q37468391-2C94134D-E583-47E8-B770-F4BB97B74A74Q37502682-FD402CE6-BE46-48B0-AEB8-17E0715CBB57Q37635255-BC82DDFA-BDC7-4F29-A7DF-66125EDC493FQ37653125-600F07F7-6CFA-4A95-A812-E62B84A215C5Q37725539-CF467448-CFEF-4E20-BBFA-0FE880FDDF94Q38010243-685AF8DB-9B58-4886-9CF8-DA65FF2F50C3Q38033468-0AA093FF-D6DE-4A52-9258-92C8B5BFD8C4Q38046641-B4FE7709-8BF0-48AD-B716-10564EC02465Q38072259-BA92DA18-3E24-4930-A035-BFB8280AFD8BQ38078436-1D40702A-0C82-4D7B-ABD2-C35D6E8E28FBQ38082848-C2E52E8F-F98E-492F-B9CF-3C9501CE82C1Q38101677-CB953908-FEE4-461C-8DEA-4E421F9AEB24Q38101993-3F5118B0-B149-4A13-97B2-4758C37F43C3Q38113092-AE01CFA1-484A-43E2-BA18-A7AE4C27F6A1Q38152405-2412BA2A-F38A-4CF5-B0D9-547C2BBC909EQ38213703-42228949-F5A8-4554-8885-0F5275603C2DQ38238949-294315EC-9743-414F-B525-ECD4DFBDE9D6Q38244576-E29082C6-93A8-43B0-80AE-51F91AA7FC3BQ38254745-5C391699-2CCD-4A2A-9DC5-E1CCDED3A5A8Q38263364-2FDE615C-E52D-4FDE-8E0A-E89066215B27Q38266290-59ED0276-B5A2-4E2F-99E5-081DEDC0FB78Q38335751-927183F2-4632-41F9-994C-093F23E9E990Q38524435-ECFB9349-E821-43A1-9F4F-F786DA56791AQ38527138-BE09253E-61AF-4EB7-8355-9D38FEFD61B7Q38751579-A045916B-C189-463D-9193-A50FF173AACEQ38845574-5B764688-7D51-4698-AFE3-280AAC9CACA8Q38920983-8E19F5EF-4FFB-4E4C-BE0A-91D82EE5CF5AQ38958933-D65A546D-2875-4EC1-860B-A01F2C757D4A
P2860
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
DPP-4 inhibitors in the manage ...... review of head-to-head trials.
@en
DPP-4 inhibitors in the manage ...... review of head-to-head trials.
@nl
type
label
DPP-4 inhibitors in the manage ...... review of head-to-head trials.
@en
DPP-4 inhibitors in the manage ...... review of head-to-head trials.
@nl
prefLabel
DPP-4 inhibitors in the manage ...... review of head-to-head trials.
@en
DPP-4 inhibitors in the manage ...... review of head-to-head trials.
@nl
P1476
DPP-4 inhibitors in the manage ...... review of head-to-head trials.
@en
P2093
A J Scheen
P304
P356
10.1016/J.DIABET.2011.11.001
P577
2011-12-22T00:00:00Z